2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer

EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study explores the real-world outcomes of neoadjuvant immunotherapy (NAIO) combined with or without chemotherapy for resectable non-small cell lung cancer (NSCLC) compared to traditional chemotherapy (NACT) alone. Conducted at Yale School of Medicine, it included patients with stage IB-IIIA NSCLC who underwent treatment followed by surgical resection between October 2015 and August 2023.<br /><br />Results indicated that patient demographics were consistent with those in the CheckMate 816 trial, with no significant differences observed in terms of age, smoking status, or clinical stage between those receiving NAIO and NACT. However, NAIO recipients often had a higher percentage or known pre-operative PD-L1 status.<br /><br />Notably, the pathologic complete response (pCR) rate was significantly higher in the NAIO group (21.7%) compared to the NACT group (6.7%). Additionally, NAIO-treated patients were less likely to receive adjuvant treatment (17.4% vs. 46.7%) and demonstrated a lower recurrence rate post-resection (17.4% vs. 36.7%). Although NAIO did not significantly impact surgical outcomes such as the extent of resection or operative time, recipients showed a trend toward better overall and disease-free survival, although this did not reach statistical significance.<br /><br />The study suggests that in real-world settings, NAIO potentially offers improved pathologic response and reduced recurrence without negatively affecting surgical outcomes, although the survival benefits observed in clinical trials like CheckMate 816 were not as statistically apparent. This could imply potential benefits of NAIO in managing resectable NSCLC, contributing to ongoing discussions regarding treatment strategies in clinical practice.

Asset Subtitle

Theresa Ermer

Meta Tag

Speaker Theresa Ermer

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

neoadjuvant immunotherapy

non-small cell lung cancer

NSCLC

chemotherapy

pathologic complete response

recurrence rate

surgical outcomes

CheckMate 816 trial

PD-L1 status

Yale School of Medicine